文献速递甲状腺核医学肿瘤 PET/CT核素与放射性配体治疗

甲状腺癌的诊疗一体化

Theranostics of Thyroid Cancer.
PubMed 文献 · Semin Nucl Med · 2024-03-19

本综述讨论分子影像与诊疗一体化在甲状腺癌中的应用。不同放射性碘同位素是分化型甲状腺癌(DTC)风险分层的核心,[18F]FDG PET/CT用于评估侵袭性和远处转移,[18F]FDOPA PET/CT是甲状腺髓样癌(MTC)最特异准确的分子影像方法;再分化策略及肽受体诊疗一体化在晚期放射性碘难治性DTC和MTC中显示有前景的结果。

要点

  • 放射性碘同位素(I131、I123、I124)是DTC风险分层的核心组成。
  • [18F]FDG PET/CT用于评估DTC侵袭性、远处转移及放射性碘难治性、低分化和未分化癌。
  • [18F]FDOPA PET/CT是MTC最特异准确的分子影像方法。

核心结论

  • 分子影像与诊疗一体化在甲状腺癌评估和管理中具有核心作用,可将肿瘤特异性分子及分子影像生物标志物纳入基于病理的风险分层体系以实现个体化治疗决策。

研究设计与样本

  • 本文为综述,讨论分子影像与诊疗一体化在甲状腺癌中的当前合适作用和未来前景。

主要发现

  • 不同放射性碘同位素(即I131、I123、I124)分子影像是分化型甲状腺癌(DTC)风险分层的核心组成部分。
  • [18F]FDG PET/CT用于评估疾病侵袭性和远处转移的存在,尤其有助于评估和风险分层放射性碘难治性DTC、低分化及未分化甲状腺癌患者。
  • [18F]FDOPA PET/CT是甲状腺髓样癌(MTC)患者最特异和准确的分子影像方法,MTC是起源于甲状腺C细胞的神经内分泌肿瘤。
  • [18F]FDG PET/CT可用于临床或生化(即血清标志物水平及动力学)表现更具侵袭性的MTC患者。
  • 除DTC的常规放射性碘治疗外,新的再分化策略现已可用于恢复放射性碘难治性DTC的摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie, I131, I123, I124) is a central component of differentiated carcinoma (DTC)'s risk stratification while [18F]F-fluorodeoxyglucose ([18F]FDG) PET/CT is interrogated about disease aggressiveness and presence of distant metastases. Moreover, it is particularly useful to assess and risk-stratify patients with radioiodine-refractory DTC, poorly differentiated, and anaplastic thyroid cancers. [18F]F-dihydroxyphenylalanine (6-[18F]FDOPA) PET/CT is the most specific and accurate molecular imaging procedure for patients with medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells. In addition, [18F]FDG PET/CT can be used in patients with more aggressive clinical or biochemical (ie, serum markers levels and kinetics) MTC phenotypes. In addition to conventional radioiodine therapy for DTC, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC. Moreover, peptide receptor theranostics showed promising results in patients with advanced and metastatic radioiodine-refractory DTC and MTC, respectively. The current appropriate role and future perspectives of molecular imaging and theranostics in thyroid cancer are discussed in our present review.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Giovanella L, Tuncel M, Aghaee A, et al. Theranostics of Thyroid Cancer. Semin Nucl Med. 2024. PMID: 38503602. doi:10.1053/j.semnuclmed.2024.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。